Prof. John Gribben | ICML 2017 | Highlights of CLL

FDA grants the Investigational New Drug designation for PBCAR20A - a CAR T-cell therapy

FDA grants the Investigational New Drug designation for PBCAR20A - a CAR T-cell therapy

What is the familial risk of developing a hematological malignancy? 

This article provides a summary of a study by Amit Sud and colleagues, which aimed to investigate the familial risks in...